| | Today's Big News Sep 15, 2022 In the wake of the Inflation Reduction Act, newer and smaller biotechs may find it increasingly difficult to succeed on their own, Amgen CEO Robert Bradway told Bloomberg. Industry experts predict as CVS, Walgreens and Amazon invest in home health and primary care, there will be major disruptions for more traditional providers, such as hospitals. After generating early evidence of efficacy, Alnylam and Regeneron have outlined plans to kick off a phase 2 trial of their RNAi candidate in the tricky NASH indication. - Gabrielle Masson | Lumanity’s research scientists and data luminaries can identify fit-for-purpose RWD and design studies to generate the strongest evidence to meet stakeholder needs. Learn more. 
|
| By Fraiser Kansteiner In an era of abundant pharma buyouts, small and midsized biotechs may find it increasingly difficult to go their own way, Amgen’s CEO Robert Bradway figures. And new drug cost legislation in the U.S. certainly won’t help, the helmsman added. |
|
|
By Heather Landi CVS, Walgreens and Amazon are ramping up their focus on in-home medical services and primary care and it will cause major disruptions for more traditional brick-and-mortar providers, industry experts say. By Nick Paul Taylor Alnylam and Regeneron have hit the gas on their RNAi nonalcoholic steatohepatitis program, outlining plans to kick off a phase 2 clinical trial of the drug candidate after generating early evidence of efficacy. By Conor Hale The postage stamp-sized Regeneten implant is designed to trigger the tissue’s healing response and be fully absorbed by the body in about six months. By Fraiser Kansteiner On the heels of Merck & Co. rival Keytruda’s green light as an adjuvant treatment for earlier-stage melanoma, Bristol Myers Squibb’s Opdivo has ginned up data suggesting it won’t be locked in advanced disease for long. By Dave Muoio Many consumers who fall on hard times will be able to maintain their coverage in the marketplace, a luxury the industry hadn't seen in prior recessions, HCA Healthcare's Bill Rutherford said Tuesday during Morgan Stanley’s 20th Annual Global Healthcare Conference. By Gabrielle Masson Are we witnessing the return of SPACs? It's worth considering as Apollomics merges with Maxpro Capital Acquisition Corp.—the second such transaction in recent weeks. By Kevin Dunleavy After lots of trial and error, the FDA has finally signed off on Mallinckrodt's Terlivaz as the first approved treatment for hepatorenal syndrome (HRS) with rapid reduction in kidney function. The condition affects between 30,000 and 40,000 annually in the U.S. By Conor Hale Researchers at NYU have developed a single test they say can help determine which patients may see their cancer return after treatment with immunotherapies, as well as who may be at risk for severe side effects. By Frank Diamond Blue Cross and Blue Shield of North Carolina touted major savings thanks to improved outcomes racked up by providers and the insurer through its Blue Premier program that relies heavily on value-based healthcare. By James Waldron It’s been a turbulent first year for IMV’s CEO Andrew Hall. In July, the company was threatened with Nasdaq delisting. Now, IMV has initiated a significant strategic reorganization that will allow the biotech to focus on its lead, oncology asset at the expense of a third of his workforce. By Fraiser Kansteiner In a write-up of Alvotehc's Reykjavik, Iceland, manufacturing facility, the FDA laid out 13 observations, including chidings related to procedural controls, management of manufacturing deviations, the presence of bacteria and mold, plus more. By Max Bayer New phase 3 data of Pfizer's pentavalent meningococcal vaccine has the big pharma gearing up to go to regulators before the end of the year. The company found its new shot held up against alternatives, including GSK's offering. Fierce podcasts Don't miss an episode | This week on "Podnosis," we talk about how the emotional toll from gun violence impacts care in hospitals. We also chat about how investors are approaching the current market. |
|
|---|
|
| Wednesday, September 28, 2022 | 2pm ET / 11am PT Explore the top line items every SMB marketer should focus on when commercializing new-to-market products, including shifts in the way that HCPs interact with pharma companies post-pandemic, and more. Register now. 
|
eBook Improve your congress competitive intelligence and cut down costs by 50% Sponsored by: Ferma.AI, a Product of ZoomRx Whitepaper Advanced research requires advanced tools. The next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Sponsored by: Bio-Techne eBook Improve patient engagement, adherence, and outcomes Sponsored by: Health Catalyst Whitepaper Supporting your product development programme through experience, expertise, and efficiency. Sponsored by: Almac Pharma Services Video Can an optimized research process--including AI-powered workflow and process automation tools--help get breakthrough drugs to market faster? Sponsored by: Proscia Video Learn how a centralized platform for pathology images, metadata, and analysis results can connect previously siloed research initiatives and advance our collective understanding of tissue. Sponsored by: Proscia Whitepaper What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent Research Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics Webinar Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics Whitepaper How can we predict the ability of a preclinical drug to inadvertently cause or intentionally inhibit cytokine secretion and T cell activation Sponsored by: ReachBio | The Cell Biology Experts™ Whitepaper Read our whitepaper and dive into the way healthcare providers can digitally transform day-to-day work by streamlining costs and increasing agility by removing manual paper burdens. Sponsored by: DocuSign Research Learn how a private health insurance company uses analytics to deliver exceptional service to its employees and members Sponsored by: Genpact Custom Resource Center Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: JLL Executive Summary How a new app brings the power of CRM to a leading lab instruments provider’s field service engineers Sponsored by: Cognizant Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent Whitepaper This paper explores how Medical Affairs is increasingly playing a key leadership role in evidence planning and generation (part 3 in a series). Sponsored by: Blue Matter, strategic consultants in the life sciences Whitepaper Explore how Thermo Scientific’s Process Liquid Preparation Services can help you plan for scalable buffer preparation. Sponsored by: Thermo Fisher Scientific Research TwinRCTs require fewer patients and shorten trial timelines for rare neurodegenerative diseases. Sponsored by: Unlearn AI eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent | | |
|
